Literature DB >> 31152474

Discovery and cross-validation of peripheral blood and renal biopsy gene expression signatures from ethnically diverse kidney transplant populations.

Carlucci G Ventura1, Thomas Whisenant2, Terri Gelbart3, Daisa S R David1, Fabiana Agena1, Daniel R Salomon, Elias David-Neto1, Sunil M Kurian4.   

Abstract

We determined peripheral blood (PB) and biopsy (Bx) RNA expression signatures in a Brazilian and US cohort of kidney transplant patients. Phenotypes assigned by precise histology were: acute rejection (AR), interstitial fibrosis/tubular atrophy/chronic rejection (CR), excellent functioning transplants (TX), and glomerulonephritis recurrence (GN). Samples were analyzed on microarrays and profiles from each cohort were cross-validated on the other cohort with similar phenotypes. We discovered signatures for each tissue: (1) AR vs TX, (2) CR vs TX, and (3) GN vs TX using the Random Forests algorithm. We validated biopsies signatures of AR vs TX (area under the curve [AUC] 0.97) and CR vs TX (AUC 0.87). We also validated both PB and Bx signatures of AR vs TX and CR vs TX with varying degrees of accuracy. Several biological pathways were shared between AR and CR, suggesting similar rejection mechanisms in these 2 clinical phenotypes. Thus, we identified gene expression signatures for AR and CR in transplant patients and validated them in independent cohorts of significantly different racial/ethnic backgrounds. These results reveal that there are strong unifying immune mechanisms driving transplant diseases and identified in the signatures discovered in each cohort, suggesting that molecular diagnostics across populations are feasible despite ethnic and environmental differences.
© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  basic (laboratory) research/science; clinical research/practice; kidney transplantation/nephrology; kidney transplantation: living donor; microarray/gene array; rejection: acute; rejection: chronic

Year:  2019        PMID: 31152474      PMCID: PMC6883121          DOI: 10.1111/ajt.15482

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  28 in total

1.  Urinary-cell mRNA and acute kidney-transplant rejection.

Authors:  Manikkam Suthanthiran; Thangamani Muthukumar
Journal:  N Engl J Med       Date:  2013-11-07       Impact factor: 91.245

2.  Molecular diagnosis of T cell-mediated rejection in human kidney transplant biopsies.

Authors:  J Reeve; J Sellarés; M Mengel; B Sis; A Skene; L Hidalgo; D G de Freitas; K S Famulski; P F Halloran
Journal:  Am J Transplant       Date:  2013-01-28       Impact factor: 8.086

3.  Molecular and Functional Noninvasive Immune Monitoring in the ESCAPE Study for Prediction of Subclinical Renal Allograft Rejection.

Authors:  Elena Crespo; Silke Roedder; Tara Sigdel; Szu-Chuan Hsieh; Sergio Luque; Josep Maria Cruzado; Tim Q Tran; Josep Maria Grinyó; Minnie M Sarwal; Oriol Bestard
Journal:  Transplantation       Date:  2017-06       Impact factor: 4.939

4.  Clinical significance of an early protocol biopsy in living-donor renal transplantation: ten-year experience at a single center.

Authors:  Bum Soon Choi; Mi Jung Shin; Suk Joon Shin; Young Soo Kim; Yeong Jin Choi; Yong-Soo Kim; In Sung Moon; Suk Young Kim; Yong Bok Koh; Byung Kee Bang; Chul Woo Yang
Journal:  Am J Transplant       Date:  2005-06       Impact factor: 8.086

5.  Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant.

Authors:  John J Friedewald; Sunil M Kurian; Raymond L Heilman; Thomas C Whisenant; Emilio D Poggio; Christopher Marsh; Prabhakar Baliga; Jonah Odim; Merideth M Brown; David N Ikle; Brian D Armstrong; Jane I Charette; Susan S Brietigam; Nedjema Sustento-Reodica; Lihui Zhao; Manoj Kandpal; Daniel R Salomon; Michael M Abecassis
Journal:  Am J Transplant       Date:  2018-08-31       Impact factor: 8.086

6.  The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy.

Authors:  Seiichirou Shishido; Hiroshi Asanuma; Hideo Nakai; Yoshiaki Mori; Hiroyuki Satoh; Isamu Kamimaki; Hiroshi Hataya; Masahiro Ikeda; Masataka Honda; Akira Hasegawa
Journal:  J Am Soc Nephrol       Date:  2003-04       Impact factor: 10.121

7.  A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group.

Authors:  A S Levey; J P Bosch; J B Lewis; T Greene; N Rogers; D Roth
Journal:  Ann Intern Med       Date:  1999-03-16       Impact factor: 25.391

8.  Orthogonal Comparison of Molecular Signatures of Kidney Transplants With Subclinical and Clinical Acute Rejection: Equivalent Performance Is Agnostic to Both Technology and Platform.

Authors:  S M Kurian; E Velazquez; R Thompson; T Whisenant; S Rose; N Riley; F Harrison; T Gelbart; J J Friedewald; J Charette; S Brietigam; J Peysakhovich; M R First; M M Abecassis; D R Salomon
Journal:  Am J Transplant       Date:  2017-04-03       Impact factor: 8.086

9.  Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling.

Authors:  Minnie Sarwal; Mei-Sze Chua; Neeraja Kambham; Szu-Chuan Hsieh; Thomas Satterwhite; Marilyn Masek; Oscar Salvatierra
Journal:  N Engl J Med       Date:  2003-07-10       Impact factor: 91.245

10.  An analysis of early renal transplant protocol biopsies--the high incidence of subclinical tubulitis.

Authors:  R Shapiro; P Randhawa; M L Jordan; V P Scantlebury; C Vivas; A Jain; R J Corry; J McCauley; J Johnston; J Donaldson; E A Gray; I Dvorchik; T R Hakala; J J Fung; T E Starzl
Journal:  Am J Transplant       Date:  2001-05       Impact factor: 8.086

View more
  1 in total

1.  An age-independent gene signature for monitoring acute rejection in kidney transplantation.

Authors:  Brian I Shaw; Daniel K Cheng; Chaitanya R Acharya; Robert B Ettenger; Herbert Kim Lyerly; Qing Cheng; Allan D Kirk; Eileen T Chambers
Journal:  Theranostics       Date:  2020-05-25       Impact factor: 11.556

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.